Coronavirus Disease (COVID-19) Outbreak: Hypofractionated Radiotherapy in Soft Tissue Sarcomas as a Valuable Option in the Environment of Limited Medical Resources and Demands for Increased Protection of Patients

Spałek, Mateusz; Rutkowski, Piotr

doi:10.3389/fonc.2020.00993

Cited by 14 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors reported 90% of tumor necrosis in 87% of the patients after treatment, 97.5% of five-year local controls, and 48.4% of five-year OS. Perioperative hypofractionation is now extensively investigated in soft tissue sarcomas, also considered to be radioresistant tumors [20]. A particular type of hypofractionation is stereotactic body RT (SBRT) that may be also used in osteosarcoma patients in the case of oligometastases, oligoprogression, or limited-volume recurrent tumors.…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis

Spałek

Poleszczuk

Czarnecka

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

Background: Due to the rarity of osteosarcoma and limited indications for radiotherapy (RT), data on RT for this tumor are scarce. This study aimed to investigate the utilization of RT for osteosarcomas in the recent 20 years and to identify factors related to patients’ response to radiation. Methods: We performed a retrospective analysis of patients irradiated for osteosarcoma treatment. We planned to assess differences in the utilization of RT between the periods of 2000–2010 and 2011–2020, identify the risk factors associated with local progression (LP), determine whether RT-related parameters are associated with LP, and calculate patients’ survival. Results: A total of 126 patients with osteosarcoma who received 181 RT treatments were identified. We found a difference in RT techniques between RT performed in the years 2000–2010 and that performed in the years 2011–2020. LP was observed after 37 (20.4%) RT treatments. Intent of RT, distant metastases, and concomitant systemic treatment affected the risk of LP. Five-year overall survival was 33% (95% confidence interval (26%–43%)). Conclusions: RT for osteosarcoma treatment has evolved from simple two-dimensional palliative irradiation into more conformal RT applied for new indications including oligometastatic and oligoprogressive disease. RT may be a valuable treatment modality for selected patients with osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis

Spałek

Poleszczuk

Czarnecka

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the literature, several attempts of the integration of neoadjuvant CHT+RT were investigated [7,18]. Various CHT regimens may be combined with both CFRT and HFRT.…”

Section: Considerations and Available Evidencementioning

confidence: 99%

“…The conventional fractionation is 50–50.4 Gy in 25–28 fractions for 5–6 weeks; however, it is not evidence-based. Several attempts of hypofractionated RT (HFRT) were described in the literature [ 7 , 18 ]. The alpha/beta ratio of STS is presumably lower than 10 Gy and closer to radioresistant tumors such as prostate cancer [ 19 , 20 , 21 ].…”

Section: Neoadjuvant Treatment Optionsmentioning

confidence: 99%

Neoadjuvant Treatment Options in Soft Tissue Sarcomas

Spałek

Kozak

Czarnecka

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Due to the heterogeneity of soft tissue sarcomas (STS), the choice of the proper perioperative treatment regimen is challenging. Neoadjuvant therapy has attracted increasing attention due to several advantages, particularly in patients with locally advanced disease. The number of available neoadjuvant modalities is growing continuously. We may consider radiotherapy, chemotherapy, targeted therapy, radiosensitizers, hyperthermia, and their combinations. This review discusses possible neoadjuvant treatment options in STS with an emphasis on available evidence, indications for each treatment type, and related risks. Finally, we summarize current recommendations of the STS neoadjuvant therapy response assessment.

show abstract

“…Hypofractionated radiotherapy has been evaluated in extremity/truncal STS in several studies but there is no randomized evidence 53,54 . Hypofractionated RT could be considered in rather small STS (less than 10 cm), if patients can be operated on quite rapidly since it reduces considerably the duration of treatment, also considering anticipated hospital/OR resources in the postradiation window 55 …”

Section: Sts Of the Extremity And Trunkmentioning

confidence: 99%

Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID‐19 pandemic: A guide for surgical oncologists

Callegaro

Raut

Keung

et al. 2020

Journal of Surgical Oncology

View full text Add to dashboard Cite

The coronavirus disease‐2019 (COVID‐19) pandemic is deeply impacting the accessibility of cancer patients to surgery. In resource‐limited conditions, the standard of care might not be deliverable, but evidence to support alternative management strategies often exists. By revisiting available treatment options, this review provides surgical oncologists with an evidence‐based framework for treating patients with gastrointestinal stromal tumor, extremity/truncal soft tissue sarcoma, and retroperitoneal sarcoma to rapidly adapt their decision‐making to the constant evolution of the COVID‐19 pandemic.

show abstract

Coronavirus Disease (COVID-19) Outbreak: Hypofractionated Radiotherapy in Soft Tissue Sarcomas as a Valuable Option in the Environment of Limited Medical Resources and Demands for Increased Protection of Patients

Cited by 14 publications

References 32 publications

Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis

Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis

Neoadjuvant Treatment Options in Soft Tissue Sarcomas

Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID‐19 pandemic: A guide for surgical oncologists

Contact Info

Product

Resources

About